Clinical Trials Using Prexasertib

Clinical trials are research studies that involve people. The clinical trials on this list are studying Prexasertib. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-2 of 2
  • Prexasertib and Irinotecan for the Treatment of Relapsed or Refractory Desmoplastic Small Round Cell Tumor or Rhabdomyosarcoma

    This phase I / II trial studies the best dose, the side effects, and how well prexasertib and irinotecan work in treating patients with desmoplastic small cell tumor or rhabdomysosarcoma that has come back (relapsed) or does not respond to treatment (refractory). Prexasertib is a type of medication called a checkpoint kinase inhibitor. It works by stopping cancer cells from repairing damage to themselves and their deoxyribonucleic acid (DNA) (genes), which may lead to death of cancer cells. Drugs used in chemotherapy, such as irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The purpose of this study is to test whether prexasertib is a safe and effective treatment for patients with desmoplastic small round cell tumor or rhabdomyosarcoma when given with irinotecan.
    Location: Memorial Sloan Kettering Cancer Center, New York, New York

  • Prexasertib with Cyclophosphamide or Gemcitabine in Treating Children and Adolescents with Recurrent or Refractory Medulloblastoma

    This phase I trial studies the side effects and best dose of prexasertib when given together with cyclophosphamide or gemcitabine in treating younger patients with a brain tumor called medulloblastoma that has come back (recurrent) or does not respond to treatment (refractory). Prexasertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cyclophosphamide and gemcitabine , work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving prexasertib in combination with cyclophosphamide and gemcitabine may cause tumors to stop growing or to shrink for a period of time and may lessen the symptoms, such as pain, that are caused by the tumor in patients with medulloblastoma.
    Location: Saint Jude Children's Research Hospital, Memphis, Tennessee